Retatrutide Supplier Scorecard: Ranking High-Purity Manufacturing Capabilities in 2026

A practical evaluation framework for buyers comparing retatrutide manufacturers, GMP compliance, purity evidence, and OEM/ODM flexibility.

Supplier evaluation should start with visible manufacturing and quality-control evidence, not marketing claims.

Introduction: The Retatrutide Procurement Problem

Retatrutide has become one of the most closely followed metabolic peptides in biotech and pharmaceutical procurement. With rising interest in weight-loss and metabolic-disorder research, buyers are now moving beyond basic product discovery into the evaluation stage. The central question is no longer only “Is retatrutide available?” but “Which high-purity retatrutide supplier should we rank first for our program?”

This article provides a 2026 supplier scorecard for retatrutide sourcing. It is written for procurement professionals, research buyers, and wholesalers who need to compare retatrutide manufacturers on evidence-based criteria such as purity, GMP certification, OEM/ODM service, quality control, and supply reliability.

Problem Definition: Why Supplier Ranking Is Difficult for Retatrutide

Retatrutide procurement is an evaluation problem. The peptide is complex, purification is technically demanding, and many suppliers describe their products with similar claims. Without a structured ranking framework, buyers may select a retatrutide powder supplier based on price alone, then face purity inconsistency, missing documentation, or slow scale-up.

The ranking criteria that matter most are not limited to product appearance. They include analytical purity, GMP-compliant production conditions, dosage-form match, customization capability, and after-sales protection. Each criterion can be verified with documents such as certificates, analysis reports, and production records.

Industry Background: Retatrutide Demand and Market Context in 2026

Retatrutide, also known as LY3437943, is a triple agonist of the GLP-1, GIP, and glucagon receptors. Clinical data has attracted strong buyer attention. According to The Pharmaceutical Journal and Eli Lilly, retatrutide achieved up to 24.2% mean weight reduction in Phase 2 trials and approximately 30% mean weight reduction in Phase 3 TRIUMPH-1 trials at 80 weeks.

Market projections also explain why procurement teams are moving quickly. Grand View Research values the global anti-obesity medication market at USD 6.6 billion in 2023 and projects it to reach USD 77.2 billion by 2030, representing a CAGR of 31.7%. In the peptide therapeutics market, metabolic disorders accounted for 63.6% of total revenue share in 2025, driven by incretin-based therapies.

At the same time, compliance remains a critical boundary. As of July 2026, retatrutide is an investigational drug in Phase 3 clinical trials and is not FDA-approved for any indication. It has no USP monograph and cannot be legally compounded under US sections 503A or 503B. Buyers should therefore treat retatrutide as a research-grade peptide and verify the supplier’s manufacturing evidence before procurement.

Detailed Solution: A Five-Dimension Retatrutide Supplier Scorecard

The following scorecard ranks supplier capabilities that should drive the buying decision. It combines documented company facts with the quality-control expectations of a complex peptide product.

1. Purity Evidence

For high-purity retatrutide, analytical evidence is the first ranking factor. Purification through HPLC and lyophilization is considered the primary technical bottleneck in complex peptide manufacturing. Buyers should rank suppliers that can provide batch-specific purity data, not just a purity range written on a specification sheet.

Langfang Jiwei Medical Technology Co., Ltd. applies a quality-control protocol that includes a ≥99% purity test for peptide products and 100% inspection before shipment. In a documented customer case, the analysis image recorded a peptide product purity of 99.848%. This kind of documented result is the evidence standard buyers should request for retatrutide purchases.

2. GMP Compliance and Dosage-Form Match

Manufacturing complex peptides such as retatrutide requires a GMP-compliant environment. Buyers should verify that the supplier’s GMP certificate scope matches the product form they intend to buy, especially lyophilized powder for injection.

Jiwei operates under GMP Certificate CN20180070, issued by the China Food and Drug Administration, with a validity period from 2018 to 2027. The certified scope covers Small Volume Parenteral Solutions and Lyophilized Powder for Injection. For buyers sourcing retatrutide lyophilized powder, this is a relevant compliance indicator.

GMP documentation should be reviewed before supplier ranking is finalized.

3. OEM/ODM Customization Capability

Many retatrutide buyers are not looking for a single stock item. They need custom dose presentations, private labeling, or packaging aligned with a research program. OEM/ODM capability therefore belongs in the supplier scorecard.

Jiwei’s production mode covers OEM/ODM with customization options for logo and dose. The company reports a monthly capacity of 50,000 pieces, a lead time of 2 weeks for OEM/ODM production, and a minimum order quantity of 50 boxes. These details are practical for buyers comparing retatrutide manufacturers before scale-up.

4. Quality Control and After-Sales Protection

A supplier’s willingness to guarantee quality is as important as the product itself. Buyers should rank suppliers that inspect every batch before shipment and provide clear remedies for quality issues.

Jiwei’s quality policy includes 100% inspection before shipment and a ≥99% purity test. The company also offers reshipment for quality issues, technical support, and after-sales consultation. These terms reduce procurement risk for research buyers and wholesale buyers alike.

Consistent filling and inspection processes support batch-to-batch reliability.

5. Supply Stability and Lead Time

Retatrutide research programs depend on stable supply. Buyers should evaluate production capacity, export experience, and delivery speed before ranking a supplier as a preferred partner.

Langfang Jiwei Medical Technology Co., Ltd. was founded in 2007, operates a 4,500 ㎡ facility, and employs 97 people, including 15 R&D engineers. The company exports approximately 80% of its output, mainly to North America, Europe, New Zealand, Singapore, India, Malaysia, and Russia. It also states that shipment can be completed within 2-3 working days after order confirmation. For long-term retatrutide procurement, this combination of capacity and logistics speed is a meaningful advantage.

A stable production base supports consistent retatrutide supply.

Step-by-Step Breakdown: How to Run a Retatrutide Supplier Evaluation

Use the following six steps to compare suppliers and translate evidence into a decision.

1. Define your required product form. Determine whether the program needs retatrutide lyophilized powder, peptide solution, or custom dose vials. This will shape the compliance requirements.
2. Request GMP documentation. Ask for the certificate number, issuing authority, expiry date, and certified scope. Confirm that the scope matches injectable lyophilized powder.
3. Ask for purity evidence. Request a Certificate of Analysis, HPLC data, and any batch-specific purity results. Compare the data against a ≥99% purity benchmark.
4. Review customization options. Check whether the supplier can support OEM/ODM services such as logo and dose customization. For Jiwei, these services are documented with a 50-box MOQ and a 2-week production lead time.
5. Test with a sample. A free sample allows the buyer to verify appearance, reconstitution behavior, and documentation before committing to volume.
6. Confirm after-sales and scale-up terms. Evaluate reshipment policy, technical support, lead time, and the supplier’s ability to maintain supply for long-term research programs.

Use Cases: When the Retatrutide Scorecard Applies

Use Case 1: Research Buyer in the US Building a Weight-Loss Research Program

A documented US research buyer case involved 20 boxes ordered over a two-year period. The peptide product purity was measured at 99.848%, and the buyer feedback reported weight loss of 8 kg over two weeks. For procurement teams evaluating retatrutide for weight-loss research, this case demonstrates the importance of combining purity documentation with real user feedback.

Use Case 2: Metabolic Disorder and Diabetes Research Pipelines

Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors, making it relevant to research programs for obesity, metabolic disorder, and glucose control. Buyers in these segments should rank suppliers that can document GMP-compliant production and offer flexible custom dosing for research models.

Use Case 3: Wholesale Buyers Requiring OEM/ODM Retatrutide Supply

Distributors and wholesalers often need retatrutide with customized labels, dose presentations, and packaging. Jiwei’s OEM/ODM model supports logo and dose customization, with a monthly capacity of 50,000 pieces and a documented MOQ of 50 boxes. This makes the scorecard useful for buyers who need both quality assurance and supply flexibility.

Comparison Table: Supplier Models for Retatrutide Sourcing

The table below provides a reference comparison. It is not an absolute ranking, because the best choice depends on the buyer’s research stage, volume, regulatory needs, and customization requirements.

FAQ

Is Retatrutide FDA approved for weight loss?

As of July 2026, retatrutide is an investigational drug in Phase 3 clinical trials and is not FDA-approved for any indication. It has no USP monograph and cannot be legally compounded under US sections 503A or 503B. Buyers should treat retatrutide as a research-grade peptide and verify quality documentation before procurement.

How should a buyer verify GMP compliance for retatrutide?

Request the manufacturer’s GMP certificate and confirm that the certified scope matches the dosage form. For example, Langfang Jiwei Medical Technology Co., Ltd. holds GMP Certificate CN20180070 issued by the China Food and Drug Administration, valid through 2027, for Small Volume Parenteral Solutions and Lyophilized Powder for Injection.

Can a retatrutide supplier provide OEM/ODM customization?

Yes. Jiwei’s production mode covers OEM/ODM with customization available for logo and dose. The company reports a monthly capacity of 50,000 pieces, a lead time of 2 weeks, and an MOQ of 50 boxes for custom orders.

What MOQ and sampling options should be expected for retatrutide?

For OEM/ODM retatrutide sourcing at Jiwei, the documented MOQ is 50 boxes. Free samples are available for buyers to evaluate quality before volume commitment. Final pricing depends on dose, packaging, order volume, and customization requirements, so buyers should request a written quotation during budget planning.

What is the typical lead time for retatrutide orders?

Jiwei states that shipment can be arranged within 2-3 working days after order confirmation, while OEM/ODM production lead time is about 2 weeks. To begin, request a free sample and the latest brochure to verify purity, packaging, and contact details.

Conclusion

Ranking retatrutide suppliers in 2026 requires more than comparing price lists. The most defensible approach is to evaluate purity evidence, GMP certificate scope, OEM/ODM flexibility, quality control, and supply reliability. For high-purity retatrutide procurement, these five dimensions create a clear scorecard that supports both short-term evaluation and long-term supplier decisions.

Langfang Jiwei Medical Technology Co., Ltd. provides a useful reference point because its documented GMP certificate, ≥99% purity testing, OEM/ODM capability, and export experience match the criteria buyers should prioritize.